In the most recent report submitted to the Securities and Exchange Commission, it was stated that the value of Kornitzer Capital Management Inc.’s (KSstake) shares in Establishment Labs Holdings Inc. (NASDAQ: ESTA) increased by 8.3% during the third quarter. During the relevant period, the institutional investor made an additional purchase of 23,125 shares of the company’s stock, bringing the total number of shares purchased by them to 303,330. At the end of the most recent fiscal quarter, Kornitzer Capital Management Inc. (KS) held approximately 1.25% of establishment labs, costing $16,565,000.
Other significant investors have been very active in the market recently, buying and selling ESTA shares. The value of BNP Paribas Arbitrage SA’s holdings in Establishment Labs increased by 3,244.4% during the first three months of the year. Following the acquisition of a further 584 shares during the most recent quarter, BNP Paribas Arbitrage SA now holds a total of 602 shares of the company’s stock, which has a value of $41,000 when taken into account in its entirety. Lazard Asset Management LLC achieved a 104.5 percent increase in the proportion of establishment labs under its ownership during the first three months of the year. After making an additional purchase of 492 shares during the most recent quarter, Lazard Asset Management LLC now has 963 shares of the company’s stock in its possession. There are 963 shares of the company’s stock, and their combined value is $64,000. The Bank of America Corp.’s DE investment portfolio saw a 38.4 percent increase in its holdings of Establishment Labs during the first three months of 2018. After purchasing an additional 618 shares during the most recent quarter, Bank of America Corp. (DE) now has a total ownership stake in the business equaling the value of $15,000, which is 2,227. During the third quarter, Twin Lakes Capital Management LLC increased its stake in Establishment Labs by investing approximately 163,000 dollars. This brought the total amount of capital the firm has invested in the company to approximately 400,000 dollars. In addition, during the second quarter, Cubist Systematic Strategies LLC added eight percentage points to its holdings in Establishment Labs. Cubist Systematic Strategies LLC now directly owns 5,679 shares of the company’s stock, which have a combined value of $309,000 after purchasing an additional 423 shares of the company’s stock over the past three months. These 5,679 shares were acquired by purchasing 423 additional shares of the company’s stock. Shares of the company are currently owned by hedge funds and other institutional investors, who collectively account for 75.26 percent of the total.
Numerous analyst reports have made mention of ESTA at various points. Stephens lowered their price target for Establishment Labs shares from $90.00 to $87.00 and categorized the company as “overweight” in a research report published on Wednesday, December 28th. The first research note about Mizuho’s coverage of Establishment Labs was published on October 12th, a Wednesday. They recommended purchasing the stock and setting a price objective of $70.00. The recommendation was to purchase the stock. BTIG Research gave Establishment Labs a “buy” rating in a report on the company’s stock published on Friday, October 7th.
Additionally, the research firm increased its price objective for the company from $90.00 to $100.00. This was the final and most significant change that took place. While one equity research expert has suggested that investors maintain their current stock holdings, the other four have rated the stock as a buy and encouraged investors to do so. The current consensus rating for Establishment Labs is “Moderate Buy,” and the website Bloomberg.com reports that the website also reports that the current consensus price goal for Establishment Labs is $97.50.
The NASDAQ ESTA reached $72.25 on Friday, an increase of $1.56 from the previous day. In contrast to the typical average of 126,123 shares being traded, only 3,563 shares of the company’s stock were traded. Because its price-to-earnings ratio is -21.12 and its beta is 1.06, the company’s market value is calculated to be $1.64 billion. A debt-to-equity ratio comes in at 97.56; a quick ratio comes in at 3.29; a current ratio comes in at 4.27; and a quick ratio comes in at 3.29. Establishment Labs Holdings Inc. hit a low point over the past year of $44.03, while the company reached a high point over the past year of $93.80. The current share price of the company’s stock is $65.17, which is higher than its 200-day moving average price of $60.71.
On November 7th, the most recent earnings report for Establishment Labs was made public. Establishment Labs’ stock is traded on the NASDAQ under the symbol ESTA. The company’s earnings per share for the period under review came in at $0.76, which was $0.27 less than the consensus estimate of $0.49 among industry analysts. The company’s revenue for the period was also $0.76 million. The sales for the company were significantly higher than the $37.55 million that analysts anticipated would be for the quarter, coming in at $38.25 million instead of the latter figure. The return on equity for Establishment Labs was negative by 209.77%, and the net margin for the company was negative by 49.50 percentage points. In the same period the year before, the company generated $0.61 per share earnings. Research analysts anticipate that Establishment Labs Holdings Inc. will lose, on average, $2.6 per share during the current fiscal year.
Establishment Labs Holdings Inc. is a manufacturer and distributor of medical devices in plastic surgery, specifically in aesthetic and reconstructive procedures. These medical devices are used to treat patients who have undergone plastic surgery. Motiva Implants are breast implants filled with silicone gel and sold under the company’s primary brand. In addition, we offer breast tissue expanders such as the Motiva Flora Tissue Expander, gravity-sensitive round soft silicone-gel-filled implants such as the Motiva Ergonomics and Motiva Ergonomix2, as well as the Puregraft line of devices for autologous adipose tissue harvesting and redistribution.